443105-64-4

Basic information

• Product Name: N-(4-ACETYL-5-METHYL-5-PYRIDIN-3-YL-4,5-DIHYDRO-1,3,4-THIADIAZOL-2-YL)ACETAMIDE
• Synonyms: TOSLAB 865153;N-(4-ACETYL-5-METHYL-5-PYRIDIN-3-YL-4,5-DIHYDRO-1,3,4-THIADIAZOL-2-YL)ACETAMIDE
• CAS NO: 443105-64-4
• Molecular Formula: C12H14N4O2S
• Molecular Weight: 278.33
• Mol File: 443105-64-4.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(4-ACETYL-5-METHYL-5-PYRIDIN-3-YL-4,5-DIHYDRO-1,3,4-THIADIAZOL-2-YL)ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-ACETYL-5-METHYL-5-PYRIDIN-3-YL-4,5-DIHYDRO-1,3,4-THIADIAZOL-2-YL)ACETAMIDE(443105-64-4)
• EPA Substance Registry System: N-(4-ACETYL-5-METHYL-5-PYRIDIN-3-YL-4,5-DIHYDRO-1,3,4-THIADIAZOL-2-YL)ACETAMIDE(443105-64-4)

Safety Data

• Hazardous Substances Data: 443105-64-4(Hazardous Substances Data)

Upstream product

• 350-03-8 methyl-3-pyridylketone 
• 108-24-7 acetic anhydride 
• 13370-86-0 2-[1-(pyridine-3-yl)ethylidene]hydrazinecarbothioamide 

Relevant articles and documents

Synthesis and pharmacological screening of a large library of 1,3,4-thiadiazolines as innovative therapeutic tools for the treatment of prostate cancer and melanoma

Antimitotic agents are widely used in cancer chemotherapy but the numerous side effects and the onset of resistance limit their clinical efficacy. Therefore, with the purpose of discovering more selective and efficient anticancer agents to be administered alone or in combination with traditional drugs, we synthesized a large library of 1,3,4-thiadiazoline analogues, maintaining the pharmacophoric structure of an antiproliferative compound known as K858: this is a new inhibitor of kinesin Eg5, able to induce the mitotic arrest in colorectal cancer cells and in xenograft ovarian cancer cells. We screened 103 compounds to assess their antiproliferative activity on PC3 prostate cancer cell line. Two derivatives, compounds 32 (corresponding to K858) and 33, have shown to be the most effective against prostate tumor cells and also towards two melanoma cell lines (SK-MEL-5 and SK-MEL-28) at low micromolar concentrations, confirming the pharmacological activity of this scaffold and revealing the potential role of 1,3,4-thiadiazolines in the management of cancer.

THIADIAZOLINE DERIVATIVE

(wherein R1 and R4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R5 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R2 represents -C(-W)R6 or the like; R3 represents a hydrogen atom, -C(=WA)R6A, or the like) Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.